Infectious Disease Diagnostics Market Size 2024-2028

The infectious disease diagnostics market is projected to grow significantly, with a forecasted increase of USD 8.90 billion at a CAGR of 4.5% between 2023 and 2028. This growth is attributed to the rising global prevalence of infectious diseases, the development of innovative diagnostic technologies, and the increasing adoption of Point-of-Care (POC) diagnostics. Infectious diseases are responsible for about 15 million deaths annually, according to the World Health Organization, highlighting the critical need for accurate and rapid diagnostic solutions.

For more details about the industry, get the PDF sample report for free

Infectious Disease Diagnostics Market Segmentation

The infectious disease diagnostics market is divided into the following segments:

End-user:

• Hospitals
• Labs

Geography:

• North America:
  • Canada
  • US
• Europe:
  • Germany
  • UK
• Asia:
  • China
• Rest of World (ROW)

Largest Segment Driving Market Growth

The Hospitals segment is expected to experience substantial growth during the forecast period. The rising incidence of diseases such as HIV, tuberculosis, hepatitis, and sexually transmitted dieseases (STDs) or sexually transmitted infections (STIs) contributes to the growing demand for infectious disease diagnostic tools in hospitals. These facilities purchase testing kits, consumables, software, and services from suppliers, driving market expansion.

Market Dynamics

Drivers:

• The increasing prevalence of infectious diseases, such as tuberculosis, HIV, hepatitis, STIs, and respiratory infections, is the primary driver of the market. For example, HIV/AIDS was responsible for 680,000 deaths in 2020 (UNAIDS). The market's growth is fueled by the need for prompt and accurate diagnostics to manage these diseases effectively.

Trends:

• Adoption of Next-Generation Sequencing (NGS): NGS and molecular testing techniques, including PCR testing, are becoming more popular for pathogen detection.
• POC Testing: The use of Point-of-Care diagnostics is a growing trend, providing immediate results and improving patient outcomes, particularly in resource-limited settings.
• Mergers and Acquisitions: The market is witnessing an increase in mergers and acquisitions, allowing companies to expand their product offerings and improve market positioning.

Get more details by ordering the complete report

Challenges:

• The availability of counterfeit drugs in developing economies remains a significant challenge, affecting patient safety and the reliability of diagnostic results. The prevalence of counterfeit products in low-income countries can hinder accurate diagnosis and delay effective treatment.

Key Players

The key players in the infectious disease diagnostics market include:

• Abbott Laboratories
• Becton Dickinson and Co.
• Bio Rad Laboratories Inc.
• bioMerieux SA
• Danaher Corp.
• DiaSorin Spa
• F. Hoffmann La Roche Ltd.
• Genetic Signatures Ltd.
• Grifols SA
• Hologic Inc.
• Meridian Bioscience Inc.
• Meril Life Sciences Pvt. Ltd.
• OraSure Technologies Inc.
• Perkin Elmer Inc.
• QIAGEN NV
• Siemens AG
• Sysmex Corp.
• Thermo Fisher Scientific Inc.
• Trinity Biotech Plc
• Vela Diagnostics

Recent Developments

• Abbott Laboratories continues to offer diagnostic solutions for various infectious diseases, including SARS-CoV-2 and HIV-1, contributing significantly to global healthcare.